Edward Barnes, MD, MPH, explains mirikizumab’s strong remission and durable response in Crohn’s disease patients after anti-TNF failure, supporting second-line use.
Edward Barnes, MD, MPH
Advertisement
Edward Barnes, MD, MPH, is an associate professor of medicine in the division of gastroenterology and hepatology and co-director of the Multidisciplinary Inflammatory Bowel Diseases Center at the University of North Carolina at Chapel Hill.
Articles by Edward Barnes, MD, MPH
Barnes reviews 3-year VIVID-2 data showing durable remission, steroid-free control, and stable safety with mirikizumab in moderate-to-severe Crohn’s disease.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
How Dermatology PAs Can Master Rapid Diagnostic Recognition
2
STAT6, ITK Inhibitors, IL-31, & IL-18 Headline Burgeoning Pipeline in Atopic Dermatitis, with David Rosmarin, MD
3
Emerging Evidence in Atopic Dermatitis Management, With Harrison Nguyen, MD, MBA, MPH
4
Managing FCS: LPL-Targeted Therapy, Drug Rationalization, and Atherosclerosis Risk
5